移植肾急性排斥反应生物学标记物的研究进展

doi:10.13481/j.1671-587x.20190536

摘要/Abstract

摘要： 早期预测、发现和治疗移植肾急性排斥反应对于改善移植肾存活具有重要意义。目前移植肾急性排斥反应的监测方法均具有局限性，限制了其广泛应用。近年来越来越多的研究发现部分生物学标记物与移植肾急性排斥反应密切相关。本文分别总结了移植前生物学标记物如可溶性CD30（sCD30）、C-X-C趋化因子配体9（CXCL9）和C-X-C趋化因子配体10（CXCL10）等与移植肾排斥反应的相关性，同时对于移植后生物学标记物，从蛋白质组学方面阐述连接蛋白（TTN）、脂多糖结合蛋白（LBP）等一系列分子在移植肾排斥反应背景下的变化，并在基因组学研究方面阐述器官移植临床试验-04（CTOT-04）研究中用以甄别及监测急性排斥反应的干扰素诱导蛋白10（CXCL10） mRNA等基因信号与排斥反应的相关性，分析干扰素诱导蛋白9（IP-9） mRNA对于急性排斥的预测价值。本文分析miR-210、miR-223和miRNA 10a等与排斥反应的相关性，介绍美国国立卫生院儿童肾移植中应用或撤除激素抑制免疫系统的研究01（SNS01）研究中基因集DUSP1、PBEF1、PSEN1、MAPK9和NKTR在鉴别移植物急性排斥中的作用，阐述kSORT联合IFNγELISPOT检测以及tCRM评分模型在预测急性排斥反应中的价值及TruGraf在监测急性排斥反应中的意义。现就近年来与移植肾急性排斥反应相关的生物学标记物的研究进行综述，为及时诊断移植肾急性排斥反应、评估抗排斥治疗效果提供新的思路。

关键词: 肾脏移植, 排斥反应, 生物学标记, 细胞因子

中图分类号:

R392.4

朱亚香, 赵帅林, 杨关印, 高宝山. 移植肾急性排斥反应生物学标记物的研究进展[J]. 吉林大学学报(医学版), 2019, 45(05): 1182-1187.

参考文献

[1] MAS VR, MUELLER TF, ARCHER KJ, et al. Identifying biomarkers as diagnostic tools in kidney transplantation[J]. Expert Rev Mol Diagn, 2011,11(2):183-196.
[2] LO D J, KAPLAN B, KIRK A D. Biomarkers for kidney transplant rejection[J]. Nat Rev Nephrol, 2014, 10(4):215-225.
[3] FEHR T, COHEN C D. Predicting an allograft's fate[J]. Kidney Int, 2011,80(12):1254-1255.
[4] BIOMARKERS DEFINITIONS WORKING GROUP. Biomarkers and surrogate endpoints:preferred definitions and conceptual framework[J]. Clin Pharmacol Ther, 2001, 69(3):89-95.
[5] DEL PRETE G, DE CARLI M, ALMERIGOGNA F, et al. Preferential expression of CD30 by human CD4⁺ T cells producing Th2-type cytokines[J]. FASEB J, 1995,9(1):81-86.
[6] WEINER R, ZIPPERLE S, DANIEL V, et al. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection[J]. Transplantation, 1996,62(11):1606-1614.
[7] RAJAKARIAR R, JIVANJI N, VARAGUNAM M, et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection[J]. Am J Transplant, 2005,5(8):1922-1925.
[8] CINTI P, PRETAGOSTINI R, ARPINO A, et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations[J]. Transplantation, 2005,79(9):1154-1156.
[9] SENGUL S, KEVEN K, GORMEZ U, et al. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation[J]. Transplantation, 2006,81(8):1216-1219.
[10] ALTERMANN W, SCHLAF G, ROTHHOFF A, et al. High variation of individual soluble serum CD30 levels of pre-transplantation patients:sCD30 a feasible marker for prediction of kidney allograft rejection?[J]. Nephrol Dial Transplant, 2007,22(10):2795-2799.
[11] SHOOSHTARIZADEH T, MOHAMMADALI A, OSSAREH S, et al. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant[J]. Exp Clin Transplant, 2013,11(3):229-233.
[12] ROTONDI M, ROSATI A, BUONAMANO A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure[J]. Am J Transplant, 2004,4(9):1466-1474.
[13] LAZZERI E, ROTONDI M, MAZZINGHI B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy[J]. Transplantation, 2005,79(9):1215-1220.
[14] ROTONDI M, NETTI G S, LAZZERI E, et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients[J]. Transpl Int, 2010,23(5):465-475.
[15] AUGUSTINE J J, SIU D S, CLEMENTE M J, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients[J]. Am J Transplant, 2005,5(8):1971-1975.
[16] BENDJELLOUL F, DESIN T S, SHOKER A S. Donor non-specific IFN-gamma production by primed alloreactive cells as a potential screening test to predict the alloimmune response[J]. Transpl Immunol, 2004,12(2):167-176.
[17] HEEGER P S, GREENSPAN N S, KUHLENSCHMIDT S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes[J]. J Immunol, 1999,163(4):2267-2275.
[18] BELLISOLA G, TRIDENTE G, NACCHIA F, et al. Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients:preliminary results of a longitudinal study[J]. Transplant Proc, 2006,38(4):1014-1017.
[19] NAESENS M, KHATRI P, LI L, et al. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes[J]. Kidney Int, 2011,80(12):1364-1376.
[20] SIGDEL T K, GAO Y Q, HE J T, et al. Mining the human urine proteome for monitoring renal transplant injury[J]. Kidney Int, 2016,89(6):1244-1252.
[21] FREUE G V, SASAKI M, MEREDITH A, et al. Proteomic signatures in plasma during early acute renal allograft rejection[J]. Mol Cell Proteomics, 2010,9(9):1954-1967.
[22] PONGPIRUL W, CHANCHAROENTHANA W, PONGPIRUL K, et al. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients[J]. Nephrology(Carlton), 2018, 23(2):169-174.
[23] SIGDEL T K, KAUSHAL A, GRITSENKO M, et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection[J]. Proteomics Clin Appl, 2010,4(1):32-47.
[24] WU D J, ZHU D, XU M, et al. Analysis of transcriptional factors and regulation networks in patients with acute renal allograft rejection[J]. J Proteome Res, 2011,10(1):175-181.
[25] LOFTHEIM H, MIDTVEDT K, HARTMANN A, et al. Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients[J]. Transplant Res, 2012,1(1):1-9.
[26] SIGDEL T K, SALOMONIS N, NICORA C D, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics[J]. Mol Cell Proteomics, 2014,13(2):621-631.
[27] KIM S C, PAGE E K, KNECHTLE S J. Urine proteomics in kidney transplantation[J]. Transplant Rev(Orlando), 2014,28(1):15-20.
[28] PEREZ J D, SAKATA M M, COLUCCI J A, et al. Plasma proteomics for the assessment of acute renal transplant rejection[J]. Life Sci, 2016,158:111-120.
[29] ONG S, MANNON R B. Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine[J]. Transplant Rev(Orlando), 2015, 29(2):60-67.
[30] SUTHANTHIRAN M, SCHWARTZ J E, DING R C, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts[J]. N Engl J Med, 2013,369(1):20-31.
[31] FLECHNER S M, KURIAN S M, HEAD S R, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes[J]. Am J Transplant, 2004,4(9):1475-1489.
[32] VASCONCELLOS L M, SCHACHTER A D, ZHENG X X, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts[J]. Transplantation, 1998,66(5):562-566.
[33] LI B, HARTONO C, DING R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine[J]. N Engl J Med, 2001,344(13):947-954.
[34] AFANEH C, MUTHUKUMAR T, LUBETZKY M, et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts[J]. Transplantation, 2010,90(12):1381-1387.
[35] HRICIK D E, NICKERSON P, FORMICA R N, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury[J]. Am J Transplant, 2013,13(10):2634-2644.
[36] SRINIVAS T R, KAPLAN B. Urinary biomarkers and kidney transplant rejection:fine-tuning the radar[J]. Am J Transplant, 2013,13(10):2519-2521.
[37] HIRT-MINKOWSKI P, DE SERRES S A, HO J. Developing renal allograft surveillance strategies-urinary biomarkers of cellular rejection[J]. Can J Kidney Health Dis, 2015,2:28.
[38] ANGLICHEAU D, SHARMA V K, DING R C, et al. MicroRNA expression profiles predictive of human renal allograft status[J]. Proc Natl Acad Sci U S A, 2009,106(13):5330-5335.
[39] LORENZEN J M, VOLKMANN I, FIEDLER J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients[J]. Am J Transplant, 2011, 11(10):2221-2227.
[40] BETTS G, SHANKAR S, SHERSTON S, et al. Examination of serum miRNA levels in kidney transplant recipients with acute rejection[J]. Transplantation, 2014,97(4):e28-30.
[41] LI L, KHATRI P, SIGDEL T K, et al. A peripheral blood diagnostic test for acute rejection in renal transplantation[J]. Am J Transplant, 2012,12(10):2710-2718.
[42] ALLISON S J. Transplantation:Biomarkers in peripheral blood detect acute rejection[J]. Nat Rev Nephrol, 2012,8(12):681.
[43] KURIAN S M, WILLIAMS A N, GELBART T, et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling[J]. Am J Transplant, 2014,14(5):1164-1172.
[44] ROEDDER S, SIGDEL T, SALOMONIS N, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection:results of the multicenter AART study[J]. PLoS Med, 2014,11(11):e1001759.
[45] SHEN-ORR S S, TIBSHIRANI R, KHATRI P, et al. Cell type-specific gene expression differences in complex tissues[J]. Nat Methods, 2010,7(4):287-289.
[46] CRESPO E, ROEDDER S, SIGDEL T, et al. Molecular and functional noninvasive immune monitoring in the ESCAPE study for prediction of subclinical renal allograft rejection[J]. Transplantation, 2017,101(6):1400-1409.
[47] SIGDEL T K, BESTARD O, TRAN T Q, et al. A computational gene expression score for predicting immune injury in renal allografts[J]. PLoS One, 2015,10(9):e0138133.
[48] MATZ M, HEINRICH F, ZHANG Q, et al. The regulation of interferon type Ⅰ pathway-related genes RSAD2 and ETV7 specifically indicates antibody-mediated rejection after kidney transplantation[J]. Clin Transplant, 2018,32(12):e13429.
[49] BLOOM R D, BROMBERG J S, POGGIO E D, et al. Cell-free DNA and active rejection in kidney allografts[J]. J Am Soc Nephrol, 2017,28(7):2221-2232.
[50] FRIEDEWALD J J, KURIAN S M, HEILMAN R L, et al. Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant[J]. Am J Transplant, 2019,19(1):98-109.